Compare Ginkgo Bioworks Holdings Inc (DNA) vs Harmony Gold Mining Co. (HMY) Price & Performance

Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.

The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.

Harmony Gold Mining (HMY) trades at $16.84, up 2.12% today, while showing strong fundamental performance with record revenue of $73.90B in 2025 and net income of $14.38B. The stock exhibits bearish technical signals with moving averages indicating selling pressure, though RSI levels suggest potential oversold conditions. Recent earnings show mixed results with two beats and two misses in the last four quarters, while analyst consensus remains cautious with 70% hold ratings.

HMY presents a value opportunity with attractive valuation multiples (P/E 6.02, EV/EBITDA 3.54) and robust profitability metrics (ROE 46.23%, net margin 29.57%). However, investors face risks from the company's significant capital expenditure plans and gold price volatility. The transition to copper production offers long-term growth potential but requires careful monitoring of execution and market conditions.